OCUL Relative Valuation
OCUL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OCUL is overvalued; if below, it's undervalued.
Historical Valuation
Ocular Therapeutix Inc (OCUL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -11.06. The fair price of Ocular Therapeutix Inc (OCUL) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：12.15
Fair
-9.12
PE
1Y
3Y
5Y
Trailing
Forward
-7.60
EV/EBITDA
Ocular Therapeutix Inc. (OCUL) has a current EV/EBITDA of -7.60. The 5-year average EV/EBITDA is -6.60. The thresholds are as follows: Strongly Undervalued below -16.58, Undervalued between -16.58 and -11.59, Fairly Valued between -1.61 and -11.59, Overvalued between -1.61 and 3.38, and Strongly Overvalued above 3.38. The current Forward EV/EBITDA of -7.60 falls within the Historic Trend Line -Fairly Valued range.
-7.32
EV/EBIT
Ocular Therapeutix Inc. (OCUL) has a current EV/EBIT of -7.32. The 5-year average EV/EBIT is -6.98. The thresholds are as follows: Strongly Undervalued below -18.69, Undervalued between -18.69 and -12.84, Fairly Valued between -1.13 and -12.84, Overvalued between -1.13 and 4.72, and Strongly Overvalued above 4.72. The current Forward EV/EBIT of -7.32 falls within the Historic Trend Line -Fairly Valued range.
39.94
PS
Ocular Therapeutix Inc. (OCUL) has a current PS of 39.94. The 5-year average PS is 14.44. The thresholds are as follows: Strongly Undervalued below -6.42, Undervalued between -6.42 and 4.01, Fairly Valued between 24.88 and 4.01, Overvalued between 24.88 and 35.31, and Strongly Overvalued above 35.31. The current Forward PS of 39.94 falls within the Strongly Overvalued range.
-9.87
P/OCF
Ocular Therapeutix Inc. (OCUL) has a current P/OCF of -9.87. The 5-year average P/OCF is -9.85. The thresholds are as follows: Strongly Undervalued below -19.83, Undervalued between -19.83 and -14.84, Fairly Valued between -4.86 and -14.84, Overvalued between -4.86 and 0.13, and Strongly Overvalued above 0.13. The current Forward P/OCF of -9.87 falls within the Historic Trend Line -Fairly Valued range.
-10.86
P/FCF
Ocular Therapeutix Inc. (OCUL) has a current P/FCF of -10.86. The 5-year average P/FCF is -10.06. The thresholds are as follows: Strongly Undervalued below -26.23, Undervalued between -26.23 and -18.15, Fairly Valued between -1.98 and -18.15, Overvalued between -1.98 and 6.10, and Strongly Overvalued above 6.10. The current Forward P/FCF of -10.86 falls within the Historic Trend Line -Fairly Valued range.
Ocular Therapeutix Inc (OCUL) has a current Price-to-Book (P/B) ratio of 7.76. Compared to its 3-year average P/B ratio of 19.79 , the current P/B ratio is approximately -60.76% higher. Relative to its 5-year average P/B ratio of 10.66, the current P/B ratio is about -27.15% higher. Ocular Therapeutix Inc (OCUL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -14.11%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -13.33% , the current FCF yield is about -100.00% lower.
8.42
P/B
Median3y
19.79
Median5y
10.66
-8.17
FCF Yield
Median3y
-14.11
Median5y
-13.33
Competitors Valuation Multiple
The average P/S ratio for OCUL's competitors is 0.00, providing a benchmark for relative valuation. Ocular Therapeutix Inc Corp (OCUL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -5.71%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OCUL increased by 45.55% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -236.58 to -477.30.
The secondary factor is the Revenue Growth, contributed -5.71%to the performance.
Overall, the performance of OCUL in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Ocular Therapeutix Inc (OCUL) currently overvalued or undervalued?
What is Ocular Therapeutix Inc (OCUL) fair value?
How does OCUL's valuation metrics compare to the industry average?
What is the current P/B ratio for Ocular Therapeutix Inc (OCUL) as of Dec 05 2025?
What is the current FCF Yield for Ocular Therapeutix Inc (OCUL) as of Dec 05 2025?
What is the current Forward P/E ratio for Ocular Therapeutix Inc (OCUL) as of Dec 05 2025?